Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...
Pharmabiz15h
China NMPA clears Harbour BioMed’s IND application for HBM9378/SKB378 for chronic obstructive pulmonary disease treatment
Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...
WWLP-22News27d
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...
Yahoo Finance27d
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
In return, Harbour BioMed and Kelun-Biotech are eligible to receive a total of up to $970 million upfront and milestone payments, as well as tiered royalties ranging from single to double digits ...
Mena FN27d
Harbour Biomed Announces License Agreement With Windward Bio For HBM9378/SKB378, An Anti-TSLP Fully Human Antibody For Immunological Diseases
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune ...
Pharmabiz24d
Harbour BioMed announces license agreement with Windward Bio for HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases
Harbour BioMed, a global biopharmaceutical company, announced that the company and Sichuan Kelun Biotech BioPharmaceutical have entered into a license agreement with Windward Bio AG (Windward Bio) for ...
Taiwan News27d
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, ...